FCM
MIST icon

Farallon Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Farallon Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-250,000
Closed -$6.79M – 108
2019
Q2 		$6.79M Buy
+250,000
New +$5.16M 0.04% 91

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Farallon Capital Management's MIST Position: Q3 2019 in Review

Farallon Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q3 2019, closing a stake of 250,000 shares — an estimated $6.79M sold.

Farallon Capital Management first reported a position in MIST in Q2 2019 and held it in 1 quarter. The position peaked at $6.79M in Q2 2019. 23 funds tracked by Wall St. Rank hold MIST as of Q3 2019.

  • Farallon Capital Management reported no remaining Milestone Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Farallon Capital Management sold 250,000 Milestone Pharmaceuticals shares in Q3 2019, an estimated $6.79M.
  • Farallon Capital Management first reported a position in Milestone Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Farallon Capital Management's Milestone Pharmaceuticals position peaked at $6.79M in Q2 2019.
  • 23 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2019.

Based on Farallon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.